Oxford, UK: Immunocore Limited, the world’s leading TCR company focused on delivering first-in-class biological therapies that transform lives, has taken laboratory and office space at The Oxford Science Park. In its new premises on the Park, Immunocore will be focused on the development of immunotherapies for infectious diseases, complementing its cancer research at Milton Park in Oxford. The office and laboratory facilities (10,625 sq ft in total) are expected to be operational by the end of the year.
The majority of Immunocore's employees at The Oxford Science Park will be research scientists. With operations in the UK and the US, Immunocore is one of the world's leading, independent biotechnology companies. It has a robust pipeline of programmes in development, and partnerships with leading companies such as Lilly, Genentech, GlaxoSmithKline and MedImmune, the biologics division of AstraZeneca. In 2015, Immunocore raised $320 million in a Series A private financing round, and recently announced a $40 million investment from the Bill and Melinda Gates Foundation to accelerate its work in infectious diseases.
Piers Scrimshaw-Wright, Managing Director of The Oxford Science Park, said, 'We are delighted to welcome Immunocore and its employees to The Oxford Science Park. With its innovative TCR research, Immunocore is a valuable addition to the high quality science and technology ecosystem that is developing here.'
Dr Namir Hassan, Vice President, Infectious Diseases, Research Management & Support of Immunocore, said, 'The Oxford Science Park provides us with the ideal location for expansion as we continue to develop our proprietary TCR biological therapies for the treatment of infectious diseases, a growing part of our broader portfolio of therapies.'
Carter Jonas acted as property agent on behalf of The Oxford Science Park, VSL acted on behalf of Immunocore.
For more information, please contact:
The Oxford Science Park
Emma Palmer Foster, Strategic Communications Consultant
T: +44 (0)7880 787185
Eliot Forster, Chief Executive Officer/ Eva-Lotta Allan, Chief Business Officer
T: +44 (0)1235 438600
Consilium Strategic Communications (for Immunocore)
Mary-Jane Elliott/Jessica Hodgson/Chris Welsh/Laura Thornton
T: +44 (0)203 709 5700
Notes to editors
About The Oxford Science Park
The Oxford Science Park is owned and managed by Magdalen College, Oxford. Created in 1991, the Park upholds the College’s heritage and provides one of the most influential science & technology environments in the UK. There is half a million square feet of workspace accommodation across the Park, which is now home to more than 2,500 people and over 70 businesses. These range from start-ups based in the Magdalen Centre innovation hub to major international companies and include Circassia, IBM, OrganOx, OxSonics, Oxford Nanopore Technologies, Sharp Laboratories, Oxford Genetics, ProImmune and Oxford Technology Management.
In addition to being a key property investment, the Park is at the heart of Magdalen College's strategy to support discovery, innovation and entrepreneurship. It will continue to develop The Oxford Science Park as a long-term strategic asset, with ambitious plans to create an additional 300,000+ sq ft of office and laboratory space on the remaining 10+ acres of land over the next 5 years. This additional capacity will support the growth of businesses already based on the Park, providing flexible workspace accommodation, and enabling new companies to enjoy the Park’s exceptional environment and collegiate and collaborative ethos.
The Oxford Science Park is located approximately four miles south-east of Oxford city centre, just off the City’s southern ring road. It has easy access to the M40 and A34, as well as to Heathrow Airport and mainline train services. For further information, please visit: www.oxfordsp.com
Immunocore, the world’s leading TCR (T cell receptor) company, is focused on delivering first-in-class biological therapies that transform lives. The Company’s therapeutics have broad applicability across a wide range of indications, including solid tumours and infectious diseases, and can access a far wider range of targets than typical antibody-based therapies. Immunocore has demonstrated compelling single-agent efficacy with its lead programme, IMCgp100, in a solid, ‘cold’, low mutation tumour of the kind which is challenging for most currently available immuno-oncology therapeutics to address. This programme is in pivotal clinical studies as a monotherapy for the treatment of patients with metastatic uveal melanoma. Immunocore also has a pipeline of wholly-owned and partnered products in development. Partners include Genentech, GlaxoSmithKline, AstraZeneca and Lilly. Immunocore is headquartered near Oxford, UK, with offices near Philadelphia, USA. The Company is privately held by a broad international and private investor base. For more information, please visit www.immunocore.com.